{"drugs":["Coumadin","Jantoven","Warfarin Sodium"],"mono":[{"id":"671285-s-0","title":"Generic Names","mono":"Warfarin Sodium"},{"id":"671285-s-1","title":"Dosing and Indications","sub":[{"id":"671285-s-1-4","title":"Adult Dosing","mono":"<ul><li>In general, the recommended target INR is 2.5 (range, 2 to 3); an INR greater than 4 does not provide greater efficacy in most patients and increases the risk of bleeding<\/li><li><b>Atrial fibrillation - Thromboembolic disorder:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Atrial fibrillation - Thromboembolic disorder; Prophylaxis:<\/b> Initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Myocardial reinfarction; Prophylaxis:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Percutaneous transluminal coronary angioplasty:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Prosthetic cardiac valve component embolism:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Prosthetic cardiac valve component embolism; Prophylaxis:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Prosthetic cardiac valve component embolism; Prophylaxis:<\/b> (bioprosthetic mitral valve) target INR 2.5 (range, 2 to 3) for the first 3 months after valve insertion (ACCP guidelines)<\/li><li><b>Prosthetic cardiac valve component embolism; Prophylaxis:<\/b> (mechanical heart aortic valves) target INR of 2.5 (range 2 to 3) (ACCP guidelines)<\/li><li><b>Prosthetic cardiac valve component embolism; Prophylaxis:<\/b> (mechanical mitral valve, mechanical heart valves, or both, caged ball or caged disk valves) target INR of 3 (range 2.5 to 3.5)<\/li><li><b>Pulmonary embolism:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Pulmonary embolism; Prophylaxis:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Thrombosis, Post myocardial infarction; Prophylaxis:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Venous thromboembolism:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><li><b>Venous thromboembolism; Prophylaxis:<\/b> initial, 2 to 5 mg ORALLY\/IV once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg ORALLY\/IV once a day<\/li><\/ul>"},{"id":"671285-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy in pediatrics patients have not been established in randomized, controlled, clinical trials, although the use of warfarin for the treatment or prophylaxis of thrombosis is well documented "},{"id":"671285-s-1-6","title":"Dose Adjustments","mono":"<ul><li>INR; single out of range value, below or above the therapeutic INR by 0.5 or less, continue current warfarin dose and test INR within 1 to 2 weeks<\/li><li><b>discontinuing therapy:<\/b> abrupt discontinuation is suggested rather than gradual tapering of the dose (ACCP guidelines)<\/li><li><b>CYP2C9 and VKORC1 genetic variation:<\/b> initial dose, based on genotype information<\/li><li><b>expected doses range, CYP2C9 *1\/*1:<\/b> (VKORC1 GG, AG) 5 to 7 mg; (VKORC1 AA) 3 to 4 mg<\/li><li><b>expected doses range, CYP2C9 *1\/*2:<\/b> (VKORC1 GG) 5 to 7 mg; (VKORC1 AG, AA) 3 to 4 mg<\/li><li><b>expected doses range, CYP2C9 *1\/*3:<\/b> (VKORC1 GG, AG) 3 to 4 mg; (VKORC1 AA) 0.5 to 2 mg<\/li><li><b>expected doses range, CYP2C9 *2\/*2:<\/b> (VKORC1 GG, AG) 3 to 4 mg; (VKORC1 AA) 0.5 to 2 mg<\/li><li><b>expected doses range, CYP2C9 *2\/*3:<\/b> (VKORC1 GG) 3 to 4 mg; (VKORC1 AG, AA) 0.5 to 2 mg<\/li><li><b>expected doses range, CYP2C9 *3\/*3:<\/b> (VKORC1 GG, AG, AA) 0.5 to 2 mg<\/li><\/ul>"},{"id":"671285-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Atrial fibrillation - Thromboembolic disorder<\/li><li>Atrial fibrillation - Thromboembolic disorder; Prophylaxis<\/li><li>Myocardial reinfarction; Prophylaxis<\/li><li>Prosthetic cardiac valve component embolism<\/li><li>Prosthetic cardiac valve component embolism; Prophylaxis<\/li><li>Pulmonary embolism<\/li><li>Pulmonary embolism; Prophylaxis<\/li><li>Thrombosis, Post myocardial infarction; Prophylaxis<\/li><li>Venous thromboembolism<\/li><li>Venous thromboembolism; Prophylaxis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Anticoagulant therapy, Genotype-guided<\/li><li>Antiphospholipid syndrome<\/li><li>Cancer - Venous thromboembolism; Prophylaxis<\/li><li>Cerebrovascular accident, Recurrent; Prophylaxis<\/li><li>Coronary arteriosclerosis; Prophylaxis<\/li><li>Impaired left ventricular function<\/li><li>Percutaneous transluminal coronary angioplasty<\/li><\/ul>"}]},{"id":"671285-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Powder for Solution)<\/b><br\/>Warfarin can cause major or fatal bleeding. Regular monitoring of INR should be performed on all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding.<br\/><\/li><li><b>Oral (Tablet)<\/b><br\/>Warfarin can cause major or fatal bleeding. Regular monitoring of INR should be performed on all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding.<br\/><\/li><\/ul>"},{"id":"671285-s-3","title":"Contraindications\/Warnings","sub":[{"id":"671285-s-3-9","title":"Contraindications","mono":"<ul><li>Bacterial endocarditis<\/li><li>Blood dyscrasias<\/li><li>Cerebral aneurysms<\/li><li>CNS hemorrhage<\/li><li>Dissecting aorta<\/li><li>Eclampsia, preeclampsia, threatened abortion<\/li><li>Gastrointestinal, genitourinary, or respiratory tract ulcerations or overt bleeding<\/li><li>Hemorrhagic tendencies<\/li><li>Hypersensitivity to warfarin or any component of the product<\/li><li>Major regional or lumbar block anesthesia<\/li><li>Malignant hypertension<\/li><li>Pericarditis and pericardial effusion<\/li><li>Pregnancy, except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism<\/li><li>Recent or potential surgery of central nervous system or eye<\/li><li>Recent or potential traumatic surgery resulting in large open surface<\/li><li>Spinal puncture and other procedures with potential for uncontrollable bleeding<\/li><li>Unsupervised and potentially noncompliant patients<\/li><\/ul>"},{"id":"671285-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning: Warfarin can cause major or fatal bleeding. Regular monitoring of INR should be performed on all treated patients. Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding.<\/li><li>Cardiovascular: Vasculitis increases risk of toxicity<\/li><li>Cardiovascular: Hypertension increases risk of bleeding<\/li><li>Catheter Use: Indwelling catheter use increases risk of toxicity <\/li><li>Dermatologic: Necrosis or gangrene of skin and other tissues has been reported with severe cases requiring amputation; discontinuation recommended if necrosis occurs<\/li><li>Duration of Therapy: Long duration increases risk of bleeding<\/li><li>Endocrine and Metabolic: Vitamin K deficiency may increase INR response<\/li><li>Endocrine and Metabolic: Increased vitamin K intake may decrease INR response<\/li><li>Endocrine and Metabolic: Diabetes mellitus increases risk of toxicity<\/li><li>Gastrointestinal: History of gastrointestinal bleeding increases risk of bleeding<\/li><li>Gastrointestinal: Steatorrhea and diarrhea may increase INR response<\/li><li>Genetic Variation: CYP2C9 and VKORC1 genetic variation influences patient response to initial and maintenance therapy and increases risk of bleeding<\/li><li>Hematologic: Avoid use in patients with heparin-induced thrombocytopenia with or without thrombosis syndrome since potentially fatal limb ischemia, necrosis, and gangrene have been reported upon heparin discontinuation and warfarin initiation or continuance<\/li><li>Hematologic: Systemic atheroemboli and cholesterol microemboli may occur with some cases resulting in necrosis or death; discontinuation recommended if occurs<\/li><li>Hematologic: High intensity of anticoagulation, including INR greater than 4, increases risk of bleeding<\/li><li>Hematologic: History of highly variable INRs increases risk of bleeding<\/li><li>Hematologic: Polycythemia vera increases risk of toxicity<\/li><li>Hematologic: Anemia increases risk of bleeding<\/li><li>Hepatic: Moderate to severe hepatic impairment increases risk of toxicity<\/li><li>Hepatic: Hepatic disorders may increase INR response<\/li><li>Hereditary Warfarin Resistance: Hereditary warfarin resistance may decrease INR response<\/li><li>Immunologic: Infectious diseases or disturbances of intestinal flora, such as sprue or antibiotic therapy, increase risk of toxicity <\/li><li>Malignancy: Malignancy increases risk of bleeding<\/li><li>Neurologic: Cerebrovascular disease increases risk of bleeding<\/li><li>Nutritional State: Poor nutritional state may increase INR response<\/li><li>Ophthalmic: Use caution during eye surgery as significantly increased risk of minor complications of sharp needle and local anesthesia block have been reported with cataract surgery<\/li><li>Protein C or S Deficiency: Hereditary or acquired protein C or protein S deficiency increases risk of tissue necrosis<\/li><li>Renal: Renal impairment increases risk of toxicity and bleeding<\/li><li>Reproductive: Use caution in pregnant women with mechanical heart valves who are at high risk of thromboembolism due to risk of fetal harm<\/li><li>Trauma: Trauma increases risk for bleeding<\/li><\/ul>"},{"id":"671285-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Warfarin: X (FDA)<\/li><li>Warfarin: D (AUS)<\/li><\/ul>"},{"id":"671285-s-3-12","title":"Breast Feeding","mono":"<ul><li>Warfarin: AAP: Maternal medication usually compatible with breast-feeding.<\/li><li>Warfarin: WHO: Compatible with breast-feeding.<\/li><li>Warfarin: Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},{"id":"671285-s-4","title":"Drug Interactions","sub":[{"id":"671285-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Tamoxifen (probable)<\/li><\/ul>"},{"id":"671285-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Acenocoumarol (theoretical)<\/li><li>Alefacept (theoretical)<\/li><li>Alipogene Tiparvovec (theoretical)<\/li><li>Alteplase, Recombinant (theoretical)<\/li><li>Amiodarone (established)<\/li><li>Amoxicillin (probable)<\/li><li>Ampicillin (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Anistreplase (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Aprepitant (probable)<\/li><li>Aspirin (theoretical)<\/li><li>Azithromycin (probable)<\/li><li>Bivalirudin (probable)<\/li><li>Blinatumomab (theoretical)<\/li><li>Capecitabine (established)<\/li><li>Carbenicillin (probable)<\/li><li>Carboplatin (probable)<\/li><li>Cefadroxil (probable)<\/li><li>Cefdinir (probable)<\/li><li>Cefepime (probable)<\/li><li>Cefixime (probable)<\/li><li>Cefotaxime (probable)<\/li><li>Cefpodoxime (probable)<\/li><li>Ceftazidime (probable)<\/li><li>Ceftibuten (probable)<\/li><li>Ceftizoxime (probable)<\/li><li>Celecoxib (probable)<\/li><li>Cephalexin (probable)<\/li><li>Cephalothin (probable)<\/li><li>Cephapirin (probable)<\/li><li>Cephradine (probable)<\/li><li>Ceritinib (theoretical)<\/li><li>Chamomile (theoretical)<\/li><li>Ciprofloxacin (probable)<\/li><li>Citalopram (probable)<\/li><li>Clarithromycin (probable)<\/li><li>Clopidogrel (theoretical)<\/li><li>Cloxacillin (established)<\/li><li>Cobicistat (theoretical)<\/li><li>Collagenase, Clostridium histolyticum (theoretical)<\/li><li>Cyclophosphamide (probable)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Dapsone (probable)<\/li><li>Darunavir (theoretical)<\/li><li>Deferasirox (theoretical)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dicloxacillin (established)<\/li><li>Dihydroartemisinin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Doxorubicin (probable)<\/li><li>Doxorubicin Hydrochloride Liposome (probable)<\/li><li>Dronedarone (probable)<\/li><li>Drotrecogin Alfa (theoretical)<\/li><li>Econazole (probable)<\/li><li>Edoxaban (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enoxacin (probable)<\/li><li>Enoxaparin (theoretical)<\/li><li>Entacapone (probable)<\/li><li>Enzalutamide (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (probable)<\/li><li>Erythromycin (established)<\/li><li>Escitalopram (probable)<\/li><li>Etoposide (probable)<\/li><li>Etravirine (theoretical)<\/li><li>Fenofibrate (theoretical)<\/li><li>Fenofibric Acid (probable)<\/li><li>Fish Oil (probable)<\/li><li>Fluconazole (established)<\/li><li>Fluorouracil (established)<\/li><li>Fluoxetine (probable)<\/li><li>Fluvoxamine (probable)<\/li><li>Garlic (probable)<\/li><li>Gatifloxacin (probable)<\/li><li>Gemifloxacin (probable)<\/li><li>Ginkgo (probable)<\/li><li>Golimumab (theoretical)<\/li><li>Iloprost (theoretical)<\/li><li>Imatinib (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Influenza Virus Vaccine (probable)<\/li><li>Itraconazole (probable)<\/li><li>Ketoconazole (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Leflunomide (probable)<\/li><li>Lepirudin (theoretical)<\/li><li>Levofloxacin (established)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lomitapide (probable)<\/li><li>Lycium (probable)<\/li><li>Marijuana (theoretical)<\/li><li>Mechlorethamine (probable)<\/li><li>Mercaptopurine (probable)<\/li><li>Methicillin (probable)<\/li><li>Methotrexate (probable)<\/li><li>Methyl Salicylate (probable)<\/li><li>Metronidazole (probable)<\/li><li>Miconazole (probable)<\/li><li>Milnacipran (probable)<\/li><li>Mirtazapine (established)<\/li><li>Moxalactam (theoretical)<\/li><li>Moxifloxacin (established)<\/li><li>Nafcillin (probable)<\/li><li>Nalidixic Acid (probable)<\/li><li>Nandrolone (theoretical)<\/li><li>Naproxen (established)<\/li><li>Nilotinib (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Nitisinone (theoretical)<\/li><li>Norfloxacin (probable)<\/li><li>Noscapine (probable)<\/li><li>Ofloxacin (probable)<\/li><li>Oritavancin (theoretical)<\/li><li>Oseltamivir (probable)<\/li><li>Oxacillin (theoretical)<\/li><li>Oxandrolone (probable)<\/li><li>Papaya (theoretical)<\/li><li>Paroxetine (probable)<\/li><li>Peginterferon Alfa-2b (theoretical)<\/li><li>Penicillin G (probable)<\/li><li>Penicillin V (probable)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Phenindione (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Piperacillin (probable)<\/li><li>Pixantrone (theoretical)<\/li><li>Posaconazole (probable)<\/li><li>Prasugrel (theoretical)<\/li><li>Procarbazine (probable)<\/li><li>Proguanil (probable)<\/li><li>Reteplase, Recombinant (theoretical)<\/li><li>Rivaroxaban (probable)<\/li><li>Ropinirole (probable)<\/li><li>Roxithromycin (probable)<\/li><li>Secukinumab (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Siltuximab (theoretical)<\/li><li>Simvastatin (established)<\/li><li>Sitaxsentan (probable)<\/li><li>St John's Wort (probable)<\/li><li>Streptokinase (theoretical)<\/li><li>Sulfamethoxazole (established)<\/li><li>Sulfinpyrazone (theoretical)<\/li><li>Sulfisoxazole (probable)<\/li><li>Tan-Shen (probable)<\/li><li>Tegafur (theoretical)<\/li><li>Telithromycin (probable)<\/li><li>Tenecteplase (theoretical)<\/li><li>Teriflunomide (probable)<\/li><li>Testosterone (probable)<\/li><li>Ticarcillin (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Tirofiban (theoretical)<\/li><li>Tocophersolan (theoretical)<\/li><li>Torsemide (probable)<\/li><li>Treprostinil (theoretical)<\/li><li>Urokinase (theoretical)<\/li><li>Valproic Acid (probable)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (probable)<\/li><li>Vincristine (probable)<\/li><li>Vincristine Sulfate Liposome (probable)<\/li><li>Vindesine (probable)<\/li><li>Vorapaxar (theoretical)<\/li><li>Voriconazole (probable)<\/li><li>Vortioxetine (theoretical)<\/li><\/ul>"},{"id":"671285-s-4-15","title":"Moderate","mono":"<ul><li>Acarbose (probable)<\/li><li>Acemetacin (probable)<\/li><li>Acetaminophen (established)<\/li><li>Allopurinol (probable)<\/li><li>Aminoglutethimide (probable)<\/li><li>Amitriptyline (probable)<\/li><li>Amprenavir (probable)<\/li><li>Apazone (probable)<\/li><li>Argatroban (probable)<\/li><li>Atovaquone (probable)<\/li><li>Avocado (probable)<\/li><li>Azathioprine (probable)<\/li><li>Balsalazide (probable)<\/li><li>Bee Pollen (probable)<\/li><li>Benorilate (probable)<\/li><li>Benzbromarone (probable)<\/li><li>Black Tea (probable)<\/li><li>Bosentan (probable)<\/li><li>Bromfenac (probable)<\/li><li>Butabarbital (probable)<\/li><li>Butalbital (probable)<\/li><li>Carbamazepine (probable)<\/li><li>Carbimazole (probable)<\/li><li>Cefamandole (probable)<\/li><li>Cefazolin (probable)<\/li><li>Ceftriaxone (probable)<\/li><li>Chitosan (probable)<\/li><li>Chloral Hydrate (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cholestyramine (probable)<\/li><li>Choline Magnesium Trisalicylate (probable)<\/li><li>Chondroitin (probable)<\/li><li>Cimetidine (probable)<\/li><li>Cisapride (probable)<\/li><li>Cisplatin (probable)<\/li><li>Coenzyme Q10 (probable)<\/li><li>Colesevelam (probable)<\/li><li>Curcumin (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Danazol (probable)<\/li><li>Desogestrel (probable)<\/li><li>Dexamethasone (probable)<\/li><li>Dexlansoprazole (probable)<\/li><li>Dextrothyroxine (probable)<\/li><li>Dienogest (probable)<\/li><li>Diflunisal (probable)<\/li><li>Disopyramide (probable)<\/li><li>Disulfiram (probable)<\/li><li>Dong Quai (probable)<\/li><li>Doxepin (probable)<\/li><li>Drospirenone (probable)<\/li><li>Duloxetine (probable)<\/li><li>Eslicarbazepine Acetate (established)<\/li><li>Esomeprazole (probable)<\/li><li>Estradiol Cypionate (probable)<\/li><li>Estradiol Valerate (probable)<\/li><li>Eterobarb (probable)<\/li><li>Ethinyl Estradiol (probable)<\/li><li>Ethynodiol Diacetate (probable)<\/li><li>Etonogestrel (probable)<\/li><li>Exenatide (probable)<\/li><li>Felbamate (probable)<\/li><li>Fluoxymesterone (probable)<\/li><li>Fluvastatin (probable)<\/li><li>Gefitinib (established)<\/li><li>Gemcitabine (probable)<\/li><li>Gemfibrozil (probable)<\/li><li>Ginger (probable)<\/li><li>Ginseng (probable)<\/li><li>Glucagon (probable)<\/li><li>Glucosamine (probable)<\/li><li>Glyburide (probable)<\/li><li>Griseofulvin (probable)<\/li><li>Heparin (probable)<\/li><li>Ifosfamide (probable)<\/li><li>Indomethacin (probable)<\/li><li>Indoprofen (probable)<\/li><li>Isoniazid (probable)<\/li><li>Isoxicam (probable)<\/li><li>Ivermectin (probable)<\/li><li>Lactulose (probable)<\/li><li>Lansoprazole (probable)<\/li><li>Levamisole (probable)<\/li><li>Levonorgestrel (probable)<\/li><li>Levothyroxine (probable)<\/li><li>Liothyronine (probable)<\/li><li>Lixisenatide (probable)<\/li><li>Lopinavir (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Medroxyprogesterone Acetate (probable)<\/li><li>Melatonin (probable)<\/li><li>Meloxicam (probable)<\/li><li>Menthol (probable)<\/li><li>Mephobarbital (probable)<\/li><li>Mesalamine (probable)<\/li><li>Mesna (probable)<\/li><li>Mestranol (probable)<\/li><li>Methimazole (probable)<\/li><li>Methylprednisolone (established)<\/li><li>Methyltestosterone (probable)<\/li><li>Methylthiouracil (probable)<\/li><li>Mitotane (probable)<\/li><li>Moricizine (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Nevirapine (probable)<\/li><li>Niacin (probable)<\/li><li>Nilutamide (probable)<\/li><li>Nimesulide (probable)<\/li><li>Norelgestromin (probable)<\/li><li>Norethindrone (probable)<\/li><li>Norgestimate (probable)<\/li><li>Norgestrel (probable)<\/li><li>Omeprazole (probable)<\/li><li>Orlistat (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Oxypurinol (probable)<\/li><li>Pantoprazole (probable)<\/li><li>Pentoxifylline (probable)<\/li><li>Phenobarbital (established)<\/li><li>Phenylbutazone (probable)<\/li><li>Phytonadione (probable)<\/li><li>Piracetam (probable)<\/li><li>Polyacrylamide (probable)<\/li><li>Potassium Iodide (probable)<\/li><li>Prednisone (probable)<\/li><li>Primidone (probable)<\/li><li>Propafenone (probable)<\/li><li>Propoxyphene (probable)<\/li><li>Propylthiouracil (probable)<\/li><li>Quetiapine (probable)<\/li><li>Ranitidine (probable)<\/li><li>Rifabutin (probable)<\/li><li>Rifampin (probable)<\/li><li>Rifapentine (probable)<\/li><li>Ritonavir (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Rosuvastatin (probable)<\/li><li>Salicylamide (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Saquinavir (probable)<\/li><li>Secobarbital (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sodium Thiosalicylate (probable)<\/li><li>Sorafenib (probable)<\/li><li>Soybean (probable)<\/li><li>Soy Isoflavones (probable)<\/li><li>Soy Protein (probable)<\/li><li>Stanozolol (probable)<\/li><li>Sucralfate (probable)<\/li><li>Sulfasalazine (probable)<\/li><li>Sulindac (probable)<\/li><li>Tenidap (probable)<\/li><li>Terbinafine (probable)<\/li><li>Thyroglobulin (probable)<\/li><li>Thyroid (probable)<\/li><li>Tibolone (established)<\/li><li>Tigecycline (probable)<\/li><li>Tolterodine (probable)<\/li><li>Tramadol (probable)<\/li><li>Trastuzumab (probable)<\/li><li>Trolamine Salicylate (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Vancomycin (probable)<\/li><li>Vemurafenib (probable)<\/li><li>Vitamin A (probable)<\/li><li>Vitamin E (probable)<\/li><li>Vorinostat (probable)<\/li><li>Zafirlukast (probable)<\/li><li>Zileuton (probable)<\/li><\/ul>"}]},{"id":"671285-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Alopecia<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cholesterol embolus syndrome, Gangrenous disorder (less than 0.1%)<\/li><li><b>Dermatologic:<\/b>Tissue necrosis (less than 0.1%)<\/li><li><b>Hematologic:<\/b>Bleeding, Hemorrhage<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Compartment syndrome<\/li><li><b>Neurologic:<\/b>Intracranial hemorrhage<\/li><li><b>Ophthalmic:<\/b>Intraocular hemorrhage<\/li><\/ul>"},{"id":"671285-s-6","title":"Drug Name Info","sub":{"0":{"id":"671285-s-6-17","title":"US Trade Names","mono":"<ul><li>Coumadin<\/li><li>Jantoven<\/li><\/ul>"},"2":{"id":"671285-s-6-19","title":"Class","mono":"<ul><li>Anticoagulant<\/li><li>Coumarin (class)<\/li><\/ul>"},"3":{"id":"671285-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"671285-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"671285-s-7","title":"Mechanism Of Action","mono":"Warfarin sodium is an anticoagulant that works by blocking the regeneration of vitamin K(1) epoxide, thus inhibiting synthesis of vitamin K-dependent clotting factors which include factors 2, 7, 9 and 10, and the anticoagulant proteins C and S.<br\/>"},{"id":"671285-s-8","title":"Pharmacokinetics","sub":[{"id":"671285-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 4 hr<\/li><li>Bioavailability, Oral: completely absorbed<\/li><li>Effect of food: no effect<\/li><\/ul>"},{"id":"671285-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 0.14 L\/kg<\/li><li>Protein binding, Plasma: 99%<\/li><\/ul>"},{"id":"671285-s-8-25","title":"Metabolism","mono":"<ul><li>Hepatic: extensive via CYP2C9 (primary isoenzyme), CYP2C19, CYP2C8, CYP2C18, CYP1A2, and CYP3A4<\/li><li>Hydroxylated warfarin metabolites: inactive<\/li><li>warfarin alcohols, minimally active<\/li><\/ul>"},{"id":"671285-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 92%<\/li><li>Bile: lesser extent<\/li><li>Total body clearance: CYP2C9*1\/*1 al&le; genotype, 0.065 mL\/min\/kg<\/li><li>Total body clearance: CYP2C9*1\/*2 or CYP2C9*1\/*3 al&le; genotypes, 0.041 mL\/min\/kg<\/li><li>Total body clearance: CYP2C9*2\/*2 or CYP2C9*2\/*3 or CYP2C9*3\/*3 al&le; genotypes, 0.02 mL\/min\/kg<\/li><\/ul>"},{"id":"671285-s-8-27","title":"Elimination Half Life","mono":"1 week <br\/>"}]},{"id":"671285-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>(injection) for IV use only; not recommended for IM administration<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute 5 mg vial with 2.7 mL sterile water for injection to yield a final concentration of 2 mg\/mL<\/li><li>administer as slow bolus injection over 1 to 2 minutes into peripheral vein<\/li><li>use reconstituted solution within 4 hours; do not refrigerate; discard unused solution<\/li><\/ul><\/li><\/ul>"},{"id":"671285-s-10","title":"Monitoring","mono":"<ul><li>INR: daily following the initial dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks; additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly; patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer)<\/li><li>INR: up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing; evaluate INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines)<\/li><li>INR; immediately prior to any dental or surgical procedure<\/li><li>INR (pediatric); more frequently to ensure target INR is achieved and maintained  the low-dose prophylactic target INR is 1.7 (range 1.5 to 1.9)<\/li><li>INR; more frequently in patients with high risk of bleeding, when starting or stopping other drugs or changing dosages of other drugs<\/li><li>INR (when administered with heparin); sample at least 5 hours after the last IV bolus dose of heparin, 4 hours after stopping continuous IV heparin infusion, 24 hours after the last subcutaneous heparin injection<\/li><li>target INR is 2.5 (range, 2 to 3) in adults and pediatric patients in most indications<\/li><li>target INR is 3 (range 2.5 to 3.5): mechanical mitral valve, mechanical heart valves in both the aortic and mitral position, those undergoing percutaneous mitral balloon valvotomy with preprocedural transesophageal echocardiogram who demonstrate a left atrial thrombus, caged ball or caged disk valves, caged ball or caged disk valves<\/li><li>signs and symptoms of necrosis and\/or gangrene of skin and other tissues<\/li><\/ul>"},{"id":"671285-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 1 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG, 10 MG<br\/><\/li><li><b>Coumadin<\/b><br\/><ul><li>Intravenous Powder for Solution: 5 MG<\/li><li>Oral Tablet: 1 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG, 10 MG<\/li><\/ul><\/li><li><b>Jantoven<\/b><br\/>Oral Tablet: 1 MG, 2 MG, 2.5 MG, 3 MG, 4 MG, 5 MG, 6 MG, 7.5 MG, 10 MG<br\/><\/li><\/ul>"},{"id":"671285-s-12","title":"Toxicology","sub":[{"id":"671285-s-12-31","title":"Clinical Effects","mono":"<b>WARFARIN AND RELATED AGENTS<\/b><br\/>USES: Therapeutic anticoagulation medication used for the treatment of deep venous thrombosis, pulmonary embolism, and other hypercoagulable states, and to prevent thromboembolic complications in patients with atrial fibrillation, prosthetic heart valves, or recent myocardial infarction. It may also be used to prevent thromboembolic complications in patients with stroke, impaired left ventricular function, or cancer. EPIDEMIOLOGY: Exposures are common. Inadvertent exposures rarely produce clinical effects. A single deliberate overdose generally does not result in coagulopathy, but a large ingestion by a patient who is chronically using warfarin may produce significant coagulopathy. Adverse events during therapeutic dosing are common. PHARMACOLOGY: Inhibits hepatic synthesis of Vitamin K dependent factors: II, VII, IX, and X, and also inhibits the activity of vitamin K 2,3-epoxide reductase. TOXICOLOGY: Excessive inhibition of factors II, VII, IX, and X can cause significant prolongation of INR and excessive bleeding after minor trauma. The risk of hemorrhage depends on patient comorbidities and severity of anticoagulation. ADVERSE EFFECTS: The primary adverse effect is bleeding, which can be more severe with comorbid conditions, such as advanced age and liver dysfunction. Warfarin can also cause skin necrosis. Warfarin is a human teratogen and increases the risk of fetal death. OVERDOSE: GENERAL: Excessive chronic doses, drug interactions, and less commonly acute overdose can cause profound anticoagulation. Effects can include bleeding at virtually any site: epistaxis, bleeding from gums, ecchymosis, hematochezia, hematuria, menorrhagia, hemarthrosis, and bleeding from minor skin or soft tissue trauma. SEVERE TOXICITY: More life-threatening complications include intracranial hemorrhage, retroperitoneal hemorrhage, or massive gastrointestinal bleed. <br\/>"},{"id":"671285-s-12-32","title":"Treatment","mono":"<b>WARFARIN AND RELATED AGENTS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Monitor INR and hemoglobin, evaluate for clinical evidence of bleeding. Warfarin should be withheld until INR approaches therapeutic range. MANAGEMENT OF SEVERE TOXICITY: Supportive care, including intravenous crystalloids, oxygen, and mechanical ventilation may be required. With significant bleeding, hemorrhagic shock may result, and patients may require transfusions of packed red blood cells and fresh frozen plasma. Products such as cryoprecipitate, and other factor concentrates may be required for severe bleeding. Vitamin K1 (5 to 10 mg) every 6 hours should also be administered, higher doses for more significant ingestions. Surgical consultation may be required depending on the extent and location of hemorrhage.<\/li><li>Decontamination: PREHOSPITAL: Emesis should probably be avoided because of the risk of subsequent bleeding. Patients on chronic anticoagulation therapy should receive activated charcoal after an acute overdose unless contraindicated.  HOSPITAL: Activated charcoal should be considered following a large, recent ingestion in a patient who does not have evidence of significant GI bleeding.<\/li><li>Antidote: PHYTONADIONE: Vitamin K1 (phytonadione): An oral formulation is preferred for patients who do not have severe hemorrhage. For acute ingestions, vitamin K1 is rarely indicated. Low dose vitamin K1 may be administered for patients with mildly elevated INRs who are clinically asymptomatic. For treatment of significantly elevated INR and\/or bleeding, the following guidelines are recommended by the American College of Chest Physicians: INR LESS THAN 5.0, NO SIGNIFICANT BLEEDING: Lower warfarin dose or omit next dose of warfarin and monitor INR; INR BETWEEN 5.0 AND 9.0, NO SIGNIFICANT BLEEDING: Omit next 1 or 2 doses of warfarin OR omit next warfarin dose and administer oral Vitamin K1 (1 to 2.5 mg). If more rapid reversal is necessary, give oral Vitamin K1 (less than or equal to 5 mg) and repeat INR in 24 hours. Give additional vitamin K1 orally (1 to 2 mg) as needed. INR GREATER THAN 9.0, NO SIGNIFICANT BLEEDING: Hold warfarin therapy and give oral Vitamin K1 (2.5 to 5 mg). Repeat INR in 24 hours. Give additional Vitamin K1, if necessary. SERIOUS BLEEDING: Hold warfarin. Administer 10 mg Vitamin K1 by slow intravenous infusion along with fresh frozen plasma, prothrombin complex concentrates (PCC), or factor VII until bleeding is controlled. Follow INR. Vitamin K1 administration may need to be repeated every 12 hours.<\/li><li>Monitoring of patient: Asymptomatic children with an inadvertent ingestion do not require any testing. Monitor INR, vital signs, and perform a clinical exam for evidence of bleeding. If the INR is normal, no additional testing is required at the time of initial evaluation, but serial INR testing over several days may be needed as the INR may not increase for several days. Monitor serial hemoglobin and\/or hematocrit in patients with prolonged INR or clinical evidence of bleeding.<\/li><li>Enhanced elimination procedure: There is no role for enhanced elimination.<\/li><li>Drug interaction: Many xenobiotics can interact with warfarin anticoagulation, both by potentiation and antagonism, either by affecting warfarin protein biding, or affecting metabolism by cytochrome P450 (CYP2C9 (primary isoenzyme), CYP2C19, CYP2C8, CYP2C18, CYP1A2, and CYP3A4).<\/li><li>Patient disposition: HOME CRITERIA: Children with inadvertent ingestions of 0.5 mg\/kg or less of warfarin can be observed at home. While children with larger single ingestions may develop prolongation of INR\/PT, clinically significant bleeding has not been reported in this setting; a PT or INR is probably NOT routinely necessary in these children unless bleeding develops. A medical evaluation may be necessary, if there is any suspicion of chronic ingestion, coingestants or in a child with a history of bleeding diathesis. OBSERVATION CRITERIA: Any patient with deliberate ingestions, a significant ingestion, or patients with comorbidities, should be referred to a health care facility for observation. Patients who are asymptomatic and who have a normal INR at baseline can be followed as an outpatient or on a psychiatric ward with twice daily INR. All symptomatic patients should be sent to a health care facility for observation. ADMISSION CRITERIA: Patients with bleeding should be admitted. Patients with significantly elevated INR, and significant comorbidities, may also require admission until the INR is improving. Patients with hypotension, or significant hemorrhage, should be admitted to an intensive care unit. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe toxicity. A hematology consult should also be considered. If significant hemorrhage develops, surgical consultation may be warranted.<\/li><\/ul>"},{"id":"671285-s-12-33","title":"Range of Toxicity","mono":"<b>WARFARIN AND RELATED AGENTS<\/b><br\/>TOXICITY: A toxic dose is highly variable. ADULT: Small ingestions (10 to 20 mg) in adults will not cause serious intoxication. However, chronic or repeated supratherapeutic ingestions of small amounts, or drug interactions in patients on a stable warfarin dose, can cause significant anticoagulation. PEDIATRIC: Greater than 0.5 mg\/kg may prolong PT\/INR; usually without bleeding. A relationship between mg\/kg ingested and amount of hypocoagulability has not yet been established. THERAPEUTIC DOSE: ADULT: INITIAL DOSE: 2 to 5 mg\/day orally with dosage adjustments based on INR response. MAINTENANCE DOSE: Range 2 to 10 mg\/day orally. PEDIATRIC: INFANTS and CHILDREN: Loading: 0.2 mg\/kg\/dose, daily for 2 days, followed by daily doses determined by the INR; Maximum: Up to 10 mg\/dose.<br\/>"}]},{"id":"671285-s-13","title":"Clinical Teaching","mono":"<ul><li>Elderly and debilitated patients are more prone to bleeding complications while taking this drug.<\/li><li>Advise patient to report signs\/symptoms of hemorrhage, skin and tissue necrosis, and hepatitis.<\/li><li>Instruct patient to avoid situations\/activities in which cuts, bruising, or injury is likely to occur. Patient should brush teeth with a soft bristle toothbrush.<\/li><li>Patient should not drink alcohol while taking this drug.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><li>Instruct patient to avoid cranberry juice or cranberry products.<\/li><li>Patient should consume approximately the same amount of vitamin K daily. Advise patient against drastic changes in diet such as eating large amounts of foods high in vitamin K (asparagus, broccoli, cabbage, brussels sprouts, spinach).<\/li><li>Patient should call healthcare professional if intravenous dose is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}]}